CureVac Statistics

Total Valuation

CureVac has a market cap or net worth of EUR 628.87 million. The enterprise value is 225.60 million.

Market Cap	628.87M
Enterprise Value	225.60M

Important Dates

The next estimated earnings date is Friday, April 25, 2025.

Earnings Date	Apr 25, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+1.57%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	125.69M

Valuation Ratios

The trailing PE ratio is 3.88.

PE Ratio	3.88
Forward PE	n/a
PS Ratio	1.18
PB Ratio	0.90
P/TBV Ratio	0.94
P/FCF Ratio	7.18
P/OCF Ratio	6.17
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 1.09, with an EV/FCF ratio of 2.58.

EV / Earnings	1.39
EV / Sales	0.46
EV / EBITDA	1.09
EV / EBIT	1.18
EV / FCF	2.58

Financial Position

The company has a current ratio of 7.28, with a Debt / Equity ratio of 0.06.

Current Ratio	7.28
Quick Ratio	7.11
Debt / Equity	0.06
Debt / EBITDA	0.17
Debt / FCF	0.45
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is 26.73% and return on invested capital (ROIC) is 20.26%.

Return on Equity (ROE)	26.73%
Return on Assets (ROA)	16.48%
Return on Invested Capital (ROIC)	20.26%
Return on Capital Employed (ROCE)	28.72%
Revenue Per Employee	592,013
Profits Per Employee	179,409
Employee Count	983
Asset Turnover	0.67
Inventory Turnover	8.34

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +20.34% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+20.34%
50-Day Moving Average	2.88
200-Day Moving Average	2.98
Relative Strength Index (RSI)	53.08
Average Volume (20 Days)	52,163

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	7.63

Income Statement

In the last 12 months, CureVac had revenue of EUR 535.18 million and earned 162.19 million in profits. Earnings per share was 0.72.

Revenue	535.18M
Gross Profit	429.55M
Operating Income	209.78M
Pretax Income	190.88M
Net Income	162.19M
EBITDA	222.56M
EBIT	209.78M
Earnings Per Share (EPS)	0.72

Full Income Statement

Balance Sheet

The company has 481.75 million in cash and 38.97 million in debt, giving a net cash position of 442.78 million.

Cash & Cash Equivalents	481.75M
Total Debt	38.97M
Net Cash	442.78M
Net Cash Per Share	n/a
Equity (Book Value)	696.61M
Book Value Per Share	3.11
Working Capital	454.07M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 101.85 million and capital expenditures -14.32 million, giving a free cash flow of 87.54 million.

Operating Cash Flow	101.85M
Capital Expenditures	-14.32M
Free Cash Flow	87.54M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 80.26%, with operating and profit margins of 39.20% and 30.30%.

Gross Margin	80.26%
Operating Margin	39.20%
Pretax Margin	35.67%
Profit Margin	30.30%
EBITDA Margin	41.59%
EBIT Margin	39.20%
FCF Margin	16.36%

Dividends & Yields

CureVac does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.57%
Shareholder Yield	-1.57%
Earnings Yield	25.79%
FCF Yield	13.92%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

CureVac has an Altman Z-Score of 3.55.

Altman Z-Score	3.55
Piotroski F-Score	n/a